Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia

NCT01685892 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01685892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 29, 2012
Completion date
August 23, 2019
Enrollment
82 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic